BioSpring GmbH
Andreas Fleischer is an accomplished professional in the field of biotechnology and quality assurance, currently serving as the Quality Assurance Manager in Operational QA at BioSpring GmbH since April 2023. Previously, Andreas held roles at Celonic Group as a Senior Process Specialist in USP and at Fresenius Medical Care as a Complaint Manager, where responsibilities included deviation management, root cause analysis, and complaint investigation. Additional experience includes optimizing fermentation processes at BASF Personal Care & Nutrition GmbH and managing projects in pharmaceutical microbiology at SGS Institut Fresenius GmbH. Andreas began their career with a diploma thesis on media and process optimization for Lactobacillus sp. during an internship at Evonik Degussa GmbH and earned a Diplom-Ingenieur (FH) in Biotechnology from Fachhochschule Darmstadt.
This person is not in any offices
BioSpring GmbH
BioSpring is a leading industry expert in oligonucleotide science and technology, specializing in high-quality cGMP manufacturing and analytics for commercial programs and clinical phases I-III, in addition to preclinical material supply and diagnostic manufacturing. We are a privately owned company of ~600 employees committed to providing expert support through all phases and regulatory filings, including highly flexible and customizable solutions to accelerate therapeutic programs through the entire drug development lifecycle. Headquartered in the center of Europe, in Frankfurt, Germany, we are an international company with a subsidiary in the United States and a local presence in Japan. Our global clients can rely on our quality and expertise, guided by our passion for innovation and more than 27 years of experience. Our aim is a highly collaborative partnership to unleash the full potential of our clients’ technology – making great strides and breakthroughs possible. We are driven by our desire for a healthier world. Restoring hope in patients living with debilitating diseases is our daily motivation to progress novel nucleic acid-based therapies to their commercial promise. Privacy notice: https://www.biospring.de/datenschutz-socialmedia/